Research & Educational Use Only. This protocol guide is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before beginning any research protocol.
Weight Loss / Metabolic StackEvidence Grade: A (Tirzepatide) / C (5-Amino-1MQ)
Tirzepatide + 5-Amino-1MQ Stack Protocol Guide
The Tirzepatide + 5-Amino-1MQ stack pairs the most effective dual incretin agonist with a novel NNMT inhibitor for a multi-pathway approach to fat loss. Tirzepatide activates both GIP and GLP-1 receptors, producing superior appetite suppression and metabolic improvement compared to single-incretin agents. 5-Amino-1MQ inhibits NNMT, an enzyme that contributes to fat cell expansion and metabolic dysfunction. By blocking NNMT, 5-Amino-1MQ increases NAD+ levels in adipose tissue, boosts cellular energy expenditure, and shrinks fat cells. Together, these compounds create powerful synergy: reduced caloric intake plus enhanced fat cell metabolism.
Tirzepatide is a dual GIP/GLP-1 receptor agonist that outperforms single-incretin agents in clinical trials (SURPASS/SURMOUNT). It produces up to 22.5% body weight reduction by suppressing appetite, slowing gastric emptying, and profoundly improving insulin sensitivity. The dual receptor activation provides metabolic benefits beyond GLP-1-only agents.
5-Amino-1MQ Synergy
5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), an enzyme upregulated in obesity that depletes NAD+ in fat cells and promotes adipocyte expansion. By blocking NNMT, this compound increases cellular NAD+, activates SIRT1 pathways in fat tissue, and increases fat cell energy expenditure. While tirzepatide reduces intake, 5-Amino-1MQ makes each fat cell burn more energy.
Combined Dosing Protocol
Protocol
Compound 1
Compound 2
Timing
Duration
Standard
Tirz 2.5mg/wk (wk1-4), 5mg (wk5-8), 7.5mg (wk9+)
5-Amino 100mg 2x/day oral
AM/PM
12-16 weeks
Aggressive
Tirz titrate to 15mg/wk
5-Amino 150mg 2x/day
AM/PM
16 weeks
Maintenance
Tirz 5mg/wk
5-Amino 100mg 1x/day
AM
8-12 weeks
Reconstitution & Preparation
Tirzepatide Preparation
Pre-filled pens (Mounjaro/Zepbound) or compounded vials
If compounded: reconstitute per pharmacy label
Store refrigerated 2-8°C
Weekly SubQ injection, same day each week
5-Amino-1MQ Preparation
Oral capsules: typically 50mg or 100mg
No reconstitution needed
Take with or without food
Store at room temperature, away from moisture
Stacking Schedule (AM/PM Timing)
AM Protocol
Morning: 5-Amino-1MQ 100mg oral with breakfast
Tirzepatide: once weekly injection (any time)
Pair with moderate exercise for best results
PM Protocol
Evening: 5-Amino-1MQ 100mg oral with dinner
Maintain adequate protein intake (1g/lb lean mass)
Stay hydrated throughout the day
Expected Timeline
Week 1-4
Tirzepatide titration at 2.5mg. Mild appetite suppression begins. 5-Amino-1MQ begins NNMT inhibition. Possible GI adjustment.
Week 5-8
Tirzepatide at 5mg. Significant appetite reduction. 5-Amino-1MQ effects compound. 6-12 lbs loss typical.
Week 9-12
Tirzepatide at 7.5-10mg. Peak synergy. Substantial weight loss of 12-20 lbs cumulative.
Week 13-16
Continued tirzepatide titration. Enhanced metabolic rate. Total 20-30+ lbs loss achievable with proper diet.
Side Effects & Monitoring
Common Side Effects
Nausea, vomiting (tirzepatide, especially early titration)
Diarrhea or constipation
Decreased appetite (therapeutic)
Injection site reactions
Mild headache (5-Amino-1MQ, uncommon)
Precautions
MTC family history - tirzepatide contraindication
Pancreatitis history
Rapid weight loss may increase gallstone risk
5-Amino-1MQ has limited long-term safety data
Not for use during pregnancy
Blood Work Recommendations
Panel
Markers
Timing
Metabolic
Fasting glucose, HbA1c, fasting insulin
Baseline, Week 8, Week 16
Lipid
Total cholesterol, LDL, HDL, triglycerides
Baseline, Week 8
Liver
ALT, AST, GGT
Baseline, Week 8
Kidney
BUN, creatinine, eGFR
Baseline, Week 12
Tirzepatide significantly improves glycemic markers. Monitor liver function as both compounds undergo hepatic processing.
